NLRP3 and renal fibrosis: Recently, it was demonstrated that gemigliptin, a dipeptidyl peptidase-4 inhibitor, mitigated UUO-induced tubular atrophy and renal fibrosis in mice by downregulating NLRP3 activity (343).